Clinical Trial Update: A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating BI-1206 in combination with Rituximab with or without Acalabrutinib in subjects with indolent …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• BI-1206
• Rituximab (rituximab)

Snippet

Sponsor: BioInvent International AB | Conditions: Indolent B-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING